TherapeuticsMD Shares Rally +27% On FBR's Initiation
Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target.
Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-identical hormone formulation. The analyst added that the formulation could even change the way women are treated with hormone replacement therapy. FBR emphasized that the company is truly a “big deal” in regards to women's health.
The analyst further noted that TherapeuticsMD may attract a large pharma partner.
Shares of TherapeuticsMD closed at $4.13 on Monday. The stock gained 27.6 percent to $5.27 before seeing some selloff. The stock is currently up 24.4 percent.
Latest Ratings for TXMD
|Apr 2016||Goldman Sachs||Initiates Coverage on||Buy|
|Jun 2015||Guggenheim||Initiates Coverage on||Buy|
|Jul 2014||FBR Capital||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.